NCT02930005

Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders

A Pilot Open-label Trial of Pentosan Polysulfate Sodium and Meclofenamic Acid As Adjunctive Treatments in Patients With Psychotic Disorders

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: The University of Texas Health Science Center, Houston · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates the feasibility of administering meclofenamic acid or pentosan polysulfate sodium as an adjunctive treatment to patients diagnosed with a psychotic disorder. Half of participants will receive meclofenamic acid, while the other half will receive polysulfate sodium.

Detailed description

Chronic, low-grade brain inflammation is involved in the development of schizophrenia and other psychotic disorders. Medications with anti-inflammatory properties, like meclofenamic acid and pentosan polysulfate may help to reduce brain inflammation and serve as a treatment of psychotic disorders.

Conditions

• Psychotic Disorders
• Schizophrenia
• Schizoaffective Disorder
• Bipolar Disorder

Interventions

Type	Name	Description
DRUG	Meclofenamic acid
DRUG	Pentosan polysulfate sodium

Timeline

• Start date: 2015-08-07
• Primary completion: 2016-10-06
• Completion: 2016-10-06
• First posted: 2016-10-11
• Last updated: 2019-03-26
• Results posted: 2019-03-26

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study